Visualising treatment effects in low-vision settings: proven and potential endpoints for clinical trials of inherited retinal disease therapies
Heath Jeffery RC, Mukhtar SA, McAllister IL, Morgan WH, Mackey DA, Chen FK. Inherited retinal diseases are the most common cause of blindness in the working-age population in Australia. Ophthalmic Genet. 2021;42:431–9.
Liew G, Michaelides M, Bunce C. A comparison of the causes of blindness certifications in England and Wales in working age adults (16-64 years), 1999-2000 with 2009-2010. BMJ Open. 2014;4:e004015.
Google Scholar
Chaumet-Riffaud AE, Chaumet-Riffaud P, Cariou A, Devisme C, Audo I, Sahel JA, et al. Impact of retinitis pigmentosa on quality of life, mental health, and employment among young adults. Am J Ophthalmol. 2017;177:169–74.
Google Scholar
Galvin O, Chi G, Brady L, Hippert C, Del Valle Rubido M, Daly A, et al. The impact of inherited retinal diseases in the Republic of Ireland (ROI) and the United Kingdom (UK) from a cost-of-illness perspective. Clin Ophthalmol. 2020;14:707–19.
Google Scholar
Gong J, Cheung S, Fasso-Opie A, Galvin O, Moniz LS, Earle D, et al. The impact of inherited retinal diseases in the United States of America (US) and Canada from a cost-of-illness perspective. Clin Ophthalmol. 2021;15:2855–66.
Google Scholar
Britten-Jones AC, Jin R, Gocuk SA, Cichello E, O’Hare F, Hickey DG, et al. The safety and efficacy of gene therapy treatment for monogenic retinal and optic nerve diseases: a systematic review. Genet Med. 2022;24:521–34.
Google Scholar
Sahel JA, Marazova K, Audo I. Clinical characteristics and current therapies for inherited retinal degenerations. Cold Spring Harb Perspect Med. 2015;5:a017111.
Google Scholar
Mack HG, Britten-Jones AC, McGuinness MB, Chen FK, Grigg JR, Jamieson RV, et al. Survey of perspectives of people with inherited retinal diseases on ocular gene therapy in Australia. Gene Ther. 2023;30:336–46.
Google Scholar
García Bohórquez B, Aller E, Rodríguez Muñoz A, Jaijo T, García García G, Millán JM. Updating the genetic landscape of inherited retinal dystrophies. Front Cell Dev Biol. 2021;9:645600.
Google Scholar
Berger W, Kloeckener-Gruissem B, Neidhardt J. The molecular basis of human retinal and vitreoretinal diseases. Prog Retin Eye Res. 2010;29:335–75.
Google Scholar
Stone EM, Andorf JL, Whitmore SS, DeLuca AP, Giacalone JC, Streb LM, et al. Clinically focused molecular investigation of 1000 consecutive families with inherited retinal disease. Ophthalmology. 2017;124:1314–31.
Google Scholar
Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet. 2006;368:1795–809.
Google Scholar
The 100,000 Genomes Project Pilot Investigators. 100,000 genomes pilot on rare-disease diagnosis in health care — preliminary report. N Engl J Med. 2021;385:1868–80.
Google Scholar
Carss KJ, Arno G, Erwood M, Stephens J, Sanchis-Juan A, Hull S, et al. Comprehensive rare variant analysis via whole-genome sequencing to determine the molecular pathology of inherited retinal disease. Am J Hum Genet. 2017;100:75–90.
Google Scholar
Lieviant JA, Chan CM, Bylstra Y, Jain K, Teo JX, Lim WW, et al. Determinants of diagnostic yield in a multi-ethnic Asian inherited retinal disease cohort. Eur J Hum Genet. 2025;21:1–9.
Hu ML, Edwards TL, O’Hare F, Hickey DG, Wang JH, Liu Z, et al. Gene therapy for inherited retinal diseases: progress and possibilities. Clin Exp Optom. 2021;104:444–54.
Google Scholar
Murro V, Banfi S, Testa F, Iarossi G, Falsini B, Sodi A, et al. A multidisciplinary approach to inherited retinal dystrophies from diagnosis to initial care: a narrative review with inputs from clinical practice. Orphanet J Rare Dis. 2023;18:223.
Google Scholar
Srinivas TR, Ho B, Kang J, Kaplan B. Post hoc analyses: after the facts. Transplantation. 2015;99:17–20.
Google Scholar
Schmetterer L, Scholl H, Garhöfer G, Janeschitz-Kriegl L, Corvi F, Sadda SR, et al. Endpoints for clinical trials in ophthalmology. Prog Retin Eye Res. 2023;2:101160.
Hamel CP. Cone rod dystrophies. Orphanet J Rare Dis. 2007;2:7.
Google Scholar
Pagon RA. Retinitis pigmentosa. Surv Ophthalmol. 1988;33:137–77.
Google Scholar
Hamel C. Retinitis pigmentosa. Orphanet J Rare Dis. 2006;1:40.
Google Scholar
Schneider N, Sundaresan Y, Gopalakrishnan P, Beryozkin A, Hanany M, Levanon EY, et al. Inherited retinal diseases: linking genes, disease-causing variants, and relevant therapeutic modalities. Prog Retin Eye Res. 2022;89:101029.
Google Scholar
Ayton LN, Rizzo JF, Bailey IL, Colenbrander A, Dagnelie G, Geruschat DR, et al. Harmonization of outcomes and vision endpoints in vision restoration trials: recommendations from the international HOVER taskforce. Transl Vis Sci Technol. 2020;9:25.
Google Scholar
Raji S, Thirunavukarasu AJ, Taylor LJ, MacLaren RE. Functional vision tests as clinical trial outcome measures in ophthalmology: a scoping review. BMJ Open. 2025;15:e097970.
Google Scholar
Murakami T, Akimoto M, Ooto S, Suzuki T, Ikeda H, Kawagoe N, et al. Association between abnormal autofluorescence and photoreceptor disorganization in retinitis pigmentosa. Am J Ophthalmol. 2008;145:687–94.
Google Scholar
Mitamura Y, Mitamura-Aizawa S, Nagasawa T, Katome T, Eguchi H, Naito T. Diagnostic imaging in patients with retinitis pigmentosa. J Med Investig. 2012;59:1–11.
Google Scholar
Whatham AR, Nguyen V, Zhu Y, Hennessy M, Kalloniatis M. The value of clinical electrophysiology in the assessment of the eye and visual system in the era of advanced imaging. Clin Exp Optom. 2014;97:99–115.
Google Scholar
Cornish EE, Vaze A, Jamieson RV, Grigg JR. The electroretinogram in the genomics era: outer retinal disorders. Eye. 2021;35:2406–18.
Google Scholar
Mahroo OA. Visual electrophysiology and “the potential of the potentials”. Eye. 2023;37:2399–408.
Google Scholar
Yang T, Justus S, Li Y, Tsang SH. BEST1: the best target for gene and cell therapies. Mol Ther. 2015;23:1805–9.
Google Scholar
Wood LJ, Jolly JK, Buckley TM, Josan AS, MacLaren RE. Low luminance visual acuity as a clinical measure and clinical trial outcome measure: a scoping review. Ophthalmic Physiol Opt. 2021;41:213–23.
Google Scholar
Yang Y, Dunbar H. Clinical perspectives and trends: microperimetry as a trial endpoint in retinal disease. Ophthalmologica. 2021;244:418–50.
Google Scholar
Zhu J, Stephenson KAJ, Dockery A, Turner J, O’Byrne JJ, Fitzsimon S, et al. Electrophysiology-guided genetic characterisation maximises molecular diagnosis in an Irish paediatric inherited retinal degeneration population. Genes. 2022;13:615.
Google Scholar
Cehajic-Kapetanovic J, Martinez-Fernandez de la Camara C, Birtel J, Rehman S, McClements ME, Charbel Issa P, et al. Impaired glutamylation of RPGRORF15 underlies the cone-dominated phenotype associated with truncating distal ORF15 variants. Proc Natl Acad Sci USA. 2022;119:e2208707119.
Google Scholar
Kousi M, Katsanis N. Genetic modifiers and oligogenic inheritance. Cold Spring Harb Perspect Med. 2015;5:a017145.
Google Scholar
Lam BL, Leroy BP, Black G, Ong T, Yoon D, Trzupek K. Genetic testing and diagnosis of inherited retinal diseases. Orphanet J Rare Dis. 2021;16:514.
Google Scholar
Yan AL, Du SW, Palczewski K. Genome editing, a superior therapy for inherited retinal diseases. Vis Res. 2023;206:108192.
Google Scholar
Xue K, MacLaren RE. Antisense oligonucleotide therapeutics in clinical trials for the treatment of inherited retinal diseases. Expert Opin Investig Drugs. 2020;29:1163–70.
Google Scholar
Lauffer MC, van Roon-Mom W, Aartsma-Rus A. Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders. Commun Med. 2024;4:1–11.
Google Scholar
da Costa BL, Levi SR, Eulau E, Tsai YT, Quinn PMJ. Prime editing for inherited retinal diseases. Front Genome Ed. 2021;3:775330.
Google Scholar
Chen X, Xu N, Li J, Zhao M, Huang L. Stem cell therapy for inherited retinal diseases: a systematic review and meta-analysis. Stem Cell Res Ther. 2023;14:286.
Google Scholar
MacLaren RE, Pearson RA, MacNeil A, Douglas RH, Salt TE, Akimoto M, et al. Retinal repair by transplantation of photoreceptor precursors. Nature. 2006;444:203–7.
Google Scholar
De Silva SR, Moore AT. Optogenetic approaches to therapy for inherited retinal degenerations. J Physiol. 2022;600:4623–32.
Google Scholar
Cehajic-Kapetanovic J, Eleftheriou C, Allen AE, Milosavljevic N, Pienaar A, Bedford R, et al. Restoration of vision with ectopic expression of human rod opsin. Curr Biol. 2015;25:2111–22.
Google Scholar
Gilhooley MJ, Lindner M, Palumaa T, Hughes S, Peirson SN, Hankins MW. A systematic comparison of optogenetic approaches to visual restoration. Mol Ther Methods Clin Dev. 2022;25:111–23.
Google Scholar
Cehajic-Kapetanovic J, Singh MS, Zrenner E, MacLaren RE. Bioengineering strategies for restoring vision. Nat Biomed Eng. 2023;7:387–404.
Google Scholar
Stingl K, Bartz-Schmidt KU, Besch D, Braun A, Bruckmann A, Gekeler F, et al. Artificial vision with wirelessly powered subretinal electronic implant alpha-IMS. Proc R Soc B Biol Sci. 2013;280:20130077.
Google Scholar
Thirunavukarasu AJ, Hu ML, Foster WP, Xue K, Cehajic-Kapetanovic J, MacLaren RE. Robot-assisted eye surgery: a systematic review of effectiveness, safety, and practicality in clinical settings. Transl Vis Sci Technol. 2024;13:20.
Google Scholar
Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390:849–60.
Google Scholar
Prasad VK. Malignant: how bad policy and bad evidence harm people with cancer. JHU Press; 2020. p. 304.
Villani E, Vujosevic S. Foreword: biomarkers and surrogate endpoints in ophthalmic clinical research. Investig Ophthalmol Visual Sci. 2017;58:BIOi-BIOii.
Thirunavukarasu AJ, Jain N, Yu HCY, Nishimura G, Tandon A, Butt H, et al. Semi-automated screening reveals patients with glaucoma-induced blindness missing out on social support: a cross-sectional study of certificate of visual impairment allocation. Br J Ophthalmol. 2025;1–6. https://doi.org/10.1136/bjo-2024-326745.
Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, et al. 2017 cardiovascular and stroke endpoint definitions for clinical trials. Circulation. 2018;137:961–72.
Google Scholar
Thirunavukarasu AJ, Jain N, Sanghera R, Lattuada F, Mahmood S, Economou A, et al. A validated web-application (GFDC) for automatic classification of glaucomatous visual field defects using Hodapp-Parrish-Anderson criteria. npj Digit Med. 2024;7:1–4.
Google Scholar
Thirunavukarasu AJ, Hassan R, Limonard A, Savant SV. Accuracy and reliability of self-administered visual acuity tests: systematic review of pragmatic trials. PLoS ONE. 2023;18:e0281847.
Google Scholar
Simunovic MP, Grigg JR, Mahroo OA. Vision at the limits: absolute threshold, visual function, and outcomes in clinical trials. Surv Ophthalmol. 2022;67:1270–86.
Google Scholar
Jolly JK, Juenemann K, Boagey H, Nadsady M, Bridge H, Maclaren RE. Validation of electronic visual acuity (EVA) measurement against standardised ETDRS charts in patients with visual field loss from inherited retinal degenerations. Br J Ophthalmol. 2020;104:924–31.
Google Scholar
Wyatt HJ, Dul MW, Swanson WH. Variability of visual field measurements is correlated with the gradient of visual sensitivity. Vis Res. 2007;47:925.
Google Scholar
Beck RW, Maguire MG, Bressler NM, Glassman AR, Lindblad AS, Ferris FL. Visual acuity as an outcome measure in clinical trials of retinal diseases. Ophthalmology. 2007;114:1804–9.
Google Scholar
MacLaren RE, Fischer MD, Gow JA, Lam BL, Sankila EMK, Girach A, et al. Subretinal timrepigene emparvovec in adult men with choroideremia: a randomized phase 3 trial. Nat Med. 2023;29:2464–72.
Google Scholar
Arditi A, Cagenello R. On the statistical reliability of letter-chart visual acuity measurements. Investig Ophthalmol. 1993;34:10.
Rabiolo A, Morales E, Afifi AA, Yu F, Nouri-Mahdavi K, Caprioli J. Quantification of visual field variability in glaucoma: implications for visual field prediction and modeling. Transl Vis Sci Technol. 2019;8:25.
Google Scholar
Chung DC, McCague S, Yu ZF, Thill S, DiStefano-Pappas J, Bennett J, et al. Novel mobility test to assess functional vision in patients with inherited retinal dystrophies. Clin Exp Ophthalmol. 2018;46:247–59.
Google Scholar
Janssen Research & Development, LLC Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene [Internet]. 2023 [cited 2023 Dec 16]. Available from: https://clinicaltrials.gov/study/NCT04671433.
Lacy GD, Abalem MF, Andrews CA, Abuzaitoun R, Popova LT, Santos EP, et al. The Michigan vision-related anxiety questionnaire: a psychosocial outcomes measure for inherited retinal degenerations. Am J Ophthalmol. 2021;225:137.
Google Scholar
Lacy GD, Abalem MF, Andrews CA, Popova LT, Santos EP, Yu G, et al. The Michigan retinal degeneration questionnaire: a patient-reported outcome instrument for inherited retinal degenerations. Am J Ophthalmol. 2021;222:60–8.
Google Scholar
Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD, et al. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001;119:1050–8.
Google Scholar
Haraldstad K, Wahl A, Andenæs R, Andersen JR, Andersen MH, Beisland E, et al. A systematic review of quality of life research in medicine and health sciences. Qual Life Res. 2019;28:2641–50.
Google Scholar
Carpenter F, Blackburn J, Jackson J, Blom A, Sayers A, Whitehouse M. Validated repeatability of patient-reported outcome measures following primary total hip replacement: a mode of delivery comparison study with randomized sequencing. Acta Orthop. 2018;89:628–33.
Google Scholar
Denniston AK, Kyte D, Calvert M, Burr JM. An introduction to patient-reported outcome measures in ophthalmic research. Eye. 2014;28:637–45.
Google Scholar
Thirunavukarasu AJ, O’Logbon J. The potential and perils of generative artificial intelligence in psychiatry and psychology. Nat Mental Health. 2024;2:745–6.
Aronson JK. Biomarkers and surrogate endpoints. Br J Clin Pharm. 2005;59:491–4.
Google Scholar
Medeiros FA. Biomarkers and surrogate endpoints: lessons learned from glaucoma. Investig Ophthalmol Vis Sci. 2017;58:BIO20–6.
Google Scholar
Medeiros FA. Biomarkers and surrogate endpoints in glaucoma clinical trials. Br J Ophthalmol. 2015;99:599–603.
Google Scholar
Kubota Vision Inc. A Phase 3 Multicenter, Randomized, Double-Masked Study Comparing the Efficacy and Safety of Emixustat Hydrochloride With Placebo for the Treatment of Macular Atrophy Secondary to Stargardt Disease [Internet]. clinicaltrials.gov; 2023 Jul [cited 2023 Sep 12]. Report No.: NCT03772665. Available from: https://clinicaltrials.gov/study/NCT03772665.
Gelman R, Smith RT, Tsang SH. Diagnostic accuracy evaluation of visual acuity and fundus autofluorescence macular geographic atrophy area for the discrimination of Stargardt groups. Retina. 2016;36:1596–601.
Google Scholar
Khanani AM, Patel SS, Staurenghi G, Tadayoni R, Danzig CJ, Eichenbaum DA, et al. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. The Lancet [Internet]. 2023 Sep 8 [cited 2023 Sep 18]; Available from: https://www.sciencedirect.com/science/article/pii/S0140673623015830.
Heier JS, Lad EM, Holz FG, Rosenfeld PJ, Guymer RH, Boyer D, et al. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet. 2023;402:1434–48.
Google Scholar
Britten-Jones AC, Thai L, Flanagan JPM, Bedggood PA, Edwards TL, Metha AB, et al. Adaptive optics imaging in inherited retinal diseases: a scoping review of the clinical literature. Surv Ophthalmol. 2024;69:51–66.
Google Scholar
Kubota R, Birch DG, Gregory JK, Koester JM. Randomised study evaluating the pharmacodynamics of emixustat hydrochloride in subjects with macular atrophy secondary to Stargardt disease. Br J Ophthalmol. 2022;106:403–8.
Google Scholar
Haraguchi Y, Chiang TK, Yu M. Application of electrophysiology in non-macular inherited retinal dystrophies. J Clin Med. 2023;12:6953.
Google Scholar
Micera A, Balzamino BO, Di Zazzo A, Dinice L, Bonini S, Coassin M. Biomarkers of neurodegeneration and precision therapy in retinal disease. Front Pharm. 2021;11:601647.
Google Scholar
Aleman TS, Miller AJ, Maguire KH, Aleman EM, Serrano LW, O’Connor KB, et al. A virtual reality orientation and mobility test for inherited retinal degenerations: testing a proof-of-concept after gene therapy. Clin Ophthalmol. 2021;15:939–52.
Google Scholar
Li Y, Gunasekeran DV, RaviChandran N, Tan TF, Ong JCL, Thirunavukarasu AJ, et al. The next generation of healthcare ecosystem in the metaverse. Biomed J. 2023;47:100679.
Shi LF, Hall AJ, Thompson DA. Full-field stimulus threshold testing: a scoping review of current practice. Eye. 2024;38:33–53.
Novartis Pharmaceuticals. Study of Efficacy and Safety of Voretigene Neparvovec in Japanese Patients With Biallelic RPE65 Mutation-associated Retinal Dystrophy [Internet]. ClinicalTrials.gov; 2020 Aug [cited 2024 Jun 22]. Available from: https://clinicaltrials.gov/study/NCT04516369.
Jolly JK, Grigg JR, McKendrick AM, Fujinami K, Cideciyan AV, Thompson DA, et al. ISCEV and IPS guideline for the full-field stimulus test (FST). Doc Ophthalmol. 2024;148:3–14.
Google Scholar
Kiraly P, Cottriall CL, Taylor LJ, Jolly JK, Cehajic-Kapetanovic J, Yusuf IH, et al. Outcomes and adverse effects of voretigene neparvovec treatment for biallelic RPE65-mediated inherited retinal dystrophies in a cohort of patients from a single center. Biomolecules. 2023;13:1484.
Google Scholar
Jolly JK, Nanda A, Buckley TMW, Pfau M, Bridge H, MacLaren RE. Assessment of scotopic function in rod–cone inherited retinal degeneration with the scotopic macular integrity assessment. Transl Vis Sci Technol. 2023;12:10.
Google Scholar
Michaelides M, Besirli CG, Yang Y, De Guimaraes TAC, Wong SC, Huckfeldt RM, et al. Phase 1/2 AAV5-hRKp.RPGR (Botaretigene Sparoparvovec) gene therapy: safety and efficacy in RPGR-associated X-linked retinitis pigmentosa. Am J Ophthalmol. 2024;267:122–34.
Google Scholar
Madheswaran G, Nasim P, Ganeshrao SB, Raman R, Ve RS. Role of microperimetry in evaluating disease progression in age-related macular degeneration: a scoping review. Int Ophthalmol. 2022;42:1975.
Google Scholar
Patino CM, Varma R, Azen SP, Conti DV, Nichol MB, McKean-Cowdin R. The impact of change in visual field on health-related quality of life: the Los Angeles Latino Eye Study. Ophthalmology. 2011;118:1310–7.
Google Scholar
Chiang PPC, Zheng Y, Wong TY, Lamoureux EL. Vision impairment and major causes of vision loss impacts on vision-specific functioning independent of socioeconomic factors. Ophthalmology. 2013;120:415–22.
Google Scholar
Csaky KG, Richman EA, Ferris FL III. Report from the NEI/FDA ophthalmic clinical trial design and endpoints symposium *. Investig Ophthalmol Vis Sci. 2008;49:479–89.
Google Scholar
Georgiou M, Fujinami K, Michaelides M. Retinal imaging in inherited retinal diseases. Ann Eye Sci. 2020;5:25.
Google Scholar
Maclaren RE, Lam BL, Fischer MD, Holz FG, Pennesi ME, Birch DG, et al. A prospective, observational, non-interventional clinical study of participants with choroideremia: the NIGHT study. Am J Ophthalmol. 2024;263:35–49.
Google Scholar
Zada M, Cornish EE, Fraser CL, Jamieson RV, Grigg JR. Natural history and clinical biomarkers of progression in X-linked retinitis pigmentosa: a systematic review. Acta Ophthalmol. 2021;99:499–510.
Google Scholar
MacLaren RE, Duncan JL, Fischer MD, Lam BL, Meunier I, Pennesi ME, et al. XOLARIS: A 24-Month, Prospective, Natural History Study of 201 Participants With RPGR-associated X-Linked Retinitis Pigmentosa. Ophthalmol Sci. 2024;5:100595.
Weinreb RN, Kaufman PL. Glaucoma research community and FDA look to the future, II: NEI/FDA glaucoma clinical trial design and endpoints symposium: measures of structural change and visual function. Investig Ophthalmol Vis Sci. 2011;52:7842–51.
Google Scholar
Sadda SR, Chakravarthy U, Birch DG, Staurenghi G, Henry EC, Brittain C. Clinical endpoints for the study of geographic atrophy secondary to age-related macular degeneration. Retina. 2016;36:1806–22.
Google Scholar
Prasad VK, Cifu AS. Ending medical reversal: improving outcomes, saving lives. JHU Press; 2015. p. 276.
link
